Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $54.33.

Several brokerages have weighed in on CLDX. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd.

Celldex Therapeutics Price Performance

Shares of CLDX stock traded up $0.90 during trading on Monday, reaching $16.84. The company's stock had a trading volume of 805,581 shares, compared to its average volume of 878,922. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.55 and a beta of 1.59. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $47.00. The stock's 50-day moving average price is $19.99 and its 200 day moving average price is $24.37.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, sell-side analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in Celldex Therapeutics by 293.2% in the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company's stock valued at $958,000 after acquiring an additional 21,013 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Celldex Therapeutics by 6.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,595 shares of the biopharmaceutical company's stock worth $3,487,000 after purchasing an additional 6,269 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 14.5% during the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after purchasing an additional 1,167,659 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at about $1,561,000. Finally, Y Intercept Hong Kong Ltd boosted its position in shares of Celldex Therapeutics by 11.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company's stock valued at $1,038,000 after purchasing an additional 3,146 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.